八部门发文！中药工业迎五年黄金发展期：新培育10个中成药大品种 推动一批中药创新药获批上市

Core Viewpoint - The "Implementation Plan for the High-Quality Development of Traditional Chinese Medicine Industry (2026-2030)" aims to establish a collaborative development system for the entire industry chain of traditional Chinese medicine by 2030, enhancing supply capabilities, technological breakthroughs, and innovation levels [1][2]. Group 1: Industry Development Goals - By 2030, the plan targets the emergence of innovative products, approval of new traditional Chinese medicine drugs, and the cultivation of 10 major traditional Chinese medicine varieties [2][3]. - The plan emphasizes the establishment of 60 high-standard raw material production bases and the construction of 5 innovation centers for traditional Chinese medicine [1][2]. Group 2: Strategic Focus Areas - Companies are encouraged to build full-chain capabilities centered on clinical value to overcome homogenization in the market, shifting from "sales-driven" to "innovation-driven" approaches [2][3]. - Emphasis on conducting high-level evidence-based medical research to provide differentiated academic evidence for products [2][3]. Group 3: Digital Transformation - The plan highlights the importance of "digital intelligence" in transitioning the traditional medicine industry from experience-based practices to modern scientific management [4][5]. - Key strategies include establishing digital quality control systems and intelligent factories to ensure product quality and compliance with regulatory standards [5][6]. Group 4: Support for Enterprises - The plan proposes actions to cultivate outstanding enterprises, including establishing development funds and providing financial services to traditional Chinese medicine companies [6]. - It aims to enhance the competitiveness of small and medium-sized enterprises in the sector and promote their modernization [6].